CTLA4 and neoplasm: DEFB1 inhibits tumor invasion and migration in OSCC, and CTLA4, a negative regulator of T cell activation, has shown efficacy in boosting anti-tumor immunity when targeted with CTLA4 inhibitors [180,181].